Titlebook: Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy; A Handbook for Diagn Maria E. Suarez-Almazor,Leonard H. Calabrese Book 20

牌帶來(lái)

Myositiscle weakness. Muscle biopsies from these patients reveal abundant CD4+ and CD8+ T cells. Importantly, as many as 25% of these patients may have co-existing myasthenia gravis and/or myocarditis. Although optimal treatment strategies remain to be defined, corticosteroids with or without other immunomodulating therapies are often effective.

arbovirus

Generosity

Benefit-Risk Considerationse therapeutic options, and, most importantly, patient values and preferences. Future research should aim to quantify risks in these special populations to ensure evidence-based decision-making that considers patient trade-offs between quality of life and survival.

FLAG

抱狗不敢前

Book 2021bination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumati

要塞

accomplishment

BLOT

現(xiàn)實(shí)

Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Arthritise effect of ICIs seen by rheumatologists. Inflammatory arthritis can have heterogeneous presentations, but, most commonly, presents as an oligoarthritis or polyarthritis. Tendons may also be involved, and imaging shows a variety of changes, including synovitis, joint effusions, tenosynovitis, enthes

ELUC

Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Polymyalgia Rheumaticatity. It remains unclear whether checkpoint inhibitor-related polymyalgia rheumatica represents the occurrence of a classic rheumatic disease or a new clinical variant with potentially different pathogenesis, clinical course, and treatment responsiveness. While these patients can present classically